14
Oct

AstraZeneca is expecting word from European regulators next week on whether they’ll recommend approval for its new ovarian cancer treatment, a drug the company hopes can bring in $2 billion a year at its peak.

…read more

Source: AstraZeneca’s $2B cancer contender lines up for EU scrutiny

    

0 No comments